Plain-English translation of NCT07053462 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a donor kidney that has been edited using CRISPR technology — a tool that removes certain immune-triggering proteins from the donor organ — can help prevent transplant rejection and allow kidneys to work longer. The edited kidney is transplanted using standard surgical techniques, and you would take standard anti-rejection medications after the procedure. The goal is to help people with end-stage kidney disease, especially those who have had difficulty finding a well-matched donor, receive a successful transplant with fewer rejection episodes.
When you receive a kidney from a donor, your immune system recognizes it as 'foreign' and tries to attack it, which is called rejection. Current anti-rejection drugs can help, but they come with serious side effects like infections and increased cancer risk. This trial exists to see whether removing the proteins that trigger this immune attack in the first place might prevent rejection more effectively and safely.
You likely qualify if…
You likely don't qualify if…
You would receive a surgery to transplant the gene-edited donor kidney into your body using standard transplant techniques. After surgery, you would take conventional anti-rejection medications as prescribed and attend regular follow-up appointments at the transplant center for blood tests, imaging, and clinical assessments. You would need to remain available for long-term follow-up care and monitoring to see how well the edited kidney works and whether it reduces rejection episodes compared to standard transplants.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China